April 21, 2026
Published by Harriet Kamendi PhD on April 21, 2026

The Questions Nobody Is Asking at the Whiteboard

Harriet Kamendi, PhD, DABT I design FDA evidence that protects capital · Regulatory Toxicologist, PhD DABT · Medical Devices · Diagnostics · Drugs · Biologics · […]
Do you like it?0
0 Read more
April 20, 2026
Published by admin on April 20, 2026

Environmental Risk Assessment in Drug Development: What It Is, Why It Matters, and When to Start

A drug can be clinically successful, commercially promising, and still carry an environmental problem nobody planned for. That usually does not show up in the first investor deck. It does not get much airtime in early product meetings. And it definitely does not sound exciting at kickoff. Until it becomes a filing issue.
Do you like it?0
0 Read more
April 17, 2026
Published by admin on April 17, 2026

Roadmaps Investors Trust

A founder says the company has a regulatory roadmap. The slide looks polished. The milestones look neat. The dates seem aggressive, but still believable. An investor flips through it and thinks one thing: Can I trust this? That is the real test.
Do you like it?0
0 Read more
April 16, 2026
Published by admin on April 16, 2026

How Roadmaps Protect Valuation

A startup can lose value long before anything officially goes wrong. No recall.No warning letter.No failed company announcement. Just growing doubt. An investor starts asking harder […]
Do you like it?0
0 Read more
Load more
gdpr-image
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.and Cookie policy
Read more
💬

Chat with us